Skip to main content
Grafa
SL Science reports tumor eradication by day 26
Image for illustrative purposes only. Not a real photo.

SL Science reports tumor eradication by day 26

Share
  • SL Science reported complete tumor eradication by day 26 in preclinical glioblastoma models at the highest tested dose.
  • SL Science shares were up 0.7% at $4.33 in premarket trading following the research update.
  • The company has submitted an FDA orphan drug designation request as it works toward clinical development.

SL Science (NASDAQ:SLBT) presented preclinical glioblastoma data showing complete tumor eradication by day 26 at an 8:1 immune-cell-to-cancer-cell ratio.

The research with Taipei Medical University, JY BioMed and HeXun Biosciences delivered expanded γδ T cells directly into tumors.

Repeated direct-to-brain dosing produced dose-dependent tumor suppression, while health screenings and blood panels found no major safety concerns, according to SL Science.

Following the announcement, SL Science's share price was up 0.7% at $4.33 in premarket trading.

SL Science submitted an FDA orphan drug designation request for its Vdelta2+ γδ T-cell glioblastoma therapy, which remains under review.

The company began Nasdaq trading in June after a business combination intended to support preclinical and planned clinical programmes targeting brain and pancreatic cancers.